Nordea Investment Management AB raised its position in shares of Solventum Co. (NYSE:SOLV - Free Report) by 189.5% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 659,887 shares of the company's stock after buying an additional 431,986 shares during the quarter. Nordea Investment Management AB owned about 0.38% of Solventum worth $43,902,000 at the end of the most recent quarter.
Other large investors also recently bought and sold shares of the company. Copeland Capital Management LLC bought a new position in Solventum during the third quarter worth $26,000. Modus Advisors LLC acquired a new stake in shares of Solventum during the fourth quarter worth $25,000. Mather Group LLC. bought a new position in shares of Solventum in the 3rd quarter worth about $27,000. Hollencrest Capital Management bought a new position in shares of Solventum in the 2nd quarter worth about $25,000. Finally, True Wealth Design LLC boosted its holdings in shares of Solventum by 23,550.0% in the 3rd quarter. True Wealth Design LLC now owns 473 shares of the company's stock valued at $33,000 after buying an additional 471 shares during the period.
Solventum Trading Down 0.8 %
Shares of NYSE:SOLV traded down $0.54 on Wednesday, hitting $68.87. The company's stock had a trading volume of 2,731,853 shares, compared to its average volume of 1,176,711. The stock's 50-day moving average is $69.50 and its two-hundred day moving average is $64.66. Solventum Co. has a 12 month low of $47.16 and a 12 month high of $96.05. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45.
Analyst Ratings Changes
Several research firms recently weighed in on SOLV. Wolfe Research began coverage on shares of Solventum in a research note on Thursday, September 26th. They set a "peer perform" rating on the stock. Morgan Stanley increased their price target on Solventum from $60.00 to $73.00 and gave the stock an "equal weight" rating in a research report on Monday, November 11th. Mizuho assumed coverage on Solventum in a research report on Wednesday, December 4th. They set a "neutral" rating and a $70.00 price objective for the company. Piper Sandler upped their price objective on Solventum from $71.00 to $75.00 and gave the stock a "neutral" rating in a research note on Friday, November 8th. Finally, Stifel Nicolaus initiated coverage on Solventum in a research note on Tuesday, October 8th. They issued a "buy" rating and a $82.00 target price on the stock. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and one has given a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $68.29.
Get Our Latest Report on SOLV
About Solventum
(
Free Report)
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.
Featured Stories
Before you consider Solventum, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Solventum wasn't on the list.
While Solventum currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
